Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide ; volume:5 ; number:1 ; day:5 ; month:3 ; year:2012 ; pages:1-10 ; date:12.2012
Journal of hematology & oncology ; 5, Heft 1 (5.3.2012), 1-10, 12.2012
- Creator
-
Sugimoto, Yuka
Sekeres, Mikkael A.
Makishima, Hideki
Traina, Fabiola
Visconte, Valeria
Jankowska, Anna
Jerez, Andres
Szpurka, Hadrian
O'Keefe, Christine L.
Guinta, Kathryn
Afable, Manuel
Tiu, Ramon
McGraw, Kathy L.
List, Alan F.
Maciejewski, Jaroslaw
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1756-8722-5-4
- URN
-
urn:nbn:de:101:1-2021081510513849732597
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sugimoto, Yuka
- Sekeres, Mikkael A.
- Makishima, Hideki
- Traina, Fabiola
- Visconte, Valeria
- Jankowska, Anna
- Jerez, Andres
- Szpurka, Hadrian
- O'Keefe, Christine L.
- Guinta, Kathryn
- Afable, Manuel
- Tiu, Ramon
- McGraw, Kathy L.
- List, Alan F.
- Maciejewski, Jaroslaw
- SpringerLink (Online service)
Other Objects (12)
Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q) : A Case Series
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Mechanism of action of lenalidomide in hematological malignancies
FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q) : A Case Series
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Mechanism of action of lenalidomide in hematological malignancies
FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q) : A Case Series
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Mechanism of action of lenalidomide in hematological malignancies
FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses